A First-in-Human Study of the Safety of Single Continuous Intravenous (IV) Infusions of CXL-1427 for up to 48 Hours in Healthy Volunteers

Status:
Completed

Trial end date:
2014-04-01

Target enrollment:

Participant gender:

This study is designed to assess a safe dosage of the drug CXL-1427 (BMS-986231) in healthy volunteers.

Phase 1

Bristol-Myers Squibb

Cardioxyl Pharmaceuticals, Inc